Nervous Times for NDA Sponsors: The New Reality of FDA Drug Reviews
This article was originally published in RPM Report
Executive Summary
FDA is adopting a broad range of procedural changes in response to suggestions from outside critics to address drug safety issues. The most significant change, however, may be just a new state of mind.
You may also be interested in...
NicOx Blood Pressure Data Positive, But Is it Enough?
Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod
NicOx Blood Pressure Data Positive, But Is it Enough?
Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod
NicOx Data Positive, But Is it Enough?
NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.